Lung cancer statistics: Prevalence and more

Lung cancer statistics can feel like the world’s least fun math quiz: lots of big numbers, lots of scary outcomes,
and absolutely no partial credit for “I didn’t inhale.” But the numbers do tell a storyone with real progress,
real gaps, and real reasons to care about prevalence (how many people are living with lung cancer) and what drives it.

This guide breaks down the latest U.S. lung cancer stats in plain English, with just enough nerdiness to be useful
and just enough humor to keep your eyes from glazing over like a donut in a break-room meeting.

Quick snapshot: the lung cancer numbers people quote most

• Estimated new cases (U.S., 2025): about 226,650.
• Estimated deaths (U.S., 2025): about 124,730still the most cancer deaths of any type.
• Prevalence (people living with lung/bronchus cancer, U.S., 2022): about 635,547.
• Lifetime risk: roughly 5.4% (about 1 in 18 people).
• Incidence rate: about 47.8 new cases per 100,000 people per year (age-adjusted).
• Death rate: about 31.5 deaths per 100,000 people per year (age-adjusted).
• Stage distribution (typical pattern): more than half are diagnosed after the cancer has spread.

First, what does “prevalence” mean (and why should you care)?

Prevalence is the number of people who are alive and living with lung cancer at a given time.
Think of it like a “how many people are in the room right now?” headcount.

That sounds simpleuntil you realize there are different ways to count the room:

• Total prevalence: everyone alive who has lung cancer (or a history of it), regardless of when they were diagnosed.
  U.S. estimates put this at about 635,547 people living with lung and bronchus cancer in 2022.
• Limited-duration prevalence: only people diagnosed within a set window. For example, the CDC reports that among
  those diagnosed from 2017–2021, about 449,627 were alive on January 1, 2022.

Here’s the key: prevalence can rise even if fewer people are getting diagnosedbecause more people are surviving longer.
In other words, better treatment can make prevalence go up (a rare case where “more” can be a sign of “better”).

How common is lung cancer in the U.S.?

Incidence: new diagnoses each year

The most widely cited national estimate for 2025 is about 226,650 new lung cancer cases.
That’s the “new this year” numberlike new subscriptions, except nobody asked for this service.

Rates help compare places and years more fairly. The NCI/SEER program reports an age-adjusted incidence rate around
47.8 new cases per 100,000 people per year, based on 2018–2022 data. Age-adjusted is important
because lung cancer is strongly tied to age; without adjustment, a state with more older adults can look “worse” even if it’s not.

Mortality: deaths each year

Lung cancer remains the leading cause of cancer death in the United States. For 2025, an estimated
124,730 people are expected to die from lung cancer. SEER reports an age-adjusted death rate around
31.5 deaths per 100,000 people per year (based on 2019–2023 mortality data).

Lifetime risk: the “what are my odds?” number

Lifetime risk answers the question people ask quietly in their head after reading scary headlines: “Could this happen to me?”
Based on recent U.S. data, about 5.4% of peopleroughly 1 in 18will be diagnosed with lung and bronchus cancer
at some point in their lifetime.

Types of lung cancer: two main buckets, different behavior

Most lung cancer statistics combine the two major types, but outcomes and treatment can differ:

• Non-small cell lung cancer (NSCLC): about 87% of cases (roughly the “most common” category).
• Small cell lung cancer (SCLC): about 13% of cases (less common, often more aggressive).

If you ever wondered why one person’s “lung cancer story” sounds completely different from someone else’s, this is a big reason.

Trends over time: why the story is improving (but not evenly)

The long-term arc in the U.S. has been encouraging: fewer people smoke than in past decades, screening exists for high-risk groups,
and treatmentsespecially targeted therapies and immunotherapyhave improved outcomes for many patients.

One headline that captures the progress: the American Lung Association reports that national lung cancer survival improved to about
29.7%, a 26% increase over the last five years (as presented in their 2025 State of Lung Cancer reporting).
That’s not “mission accomplished,” but it is meaningful movement in the right direction.

Survival rates: stage matters more than your group chat thinks

Overall survival stats are useful, but they hide the most important truth about lung cancer outcomes:
the stage at diagnosis changes the odds dramatically.

5-year survival by stage (U.S.)

The American Cancer Society summarizes 5-year relative survival by SEER stage. For NSCLC, survival is much higher when cancer is localized
(confined to the lung) and drops as it spreads. For SCLC, survival is generally lower across stages.

Translation: finding lung cancer earlier isn’t a small advantageit’s a different game.

Stage at diagnosis: why “prevalence” and “survival” are linked

So why is early detection such a big deal? Because too many cases are diagnosed late.

SEER’s national stage distribution shows about 23% diagnosed at a localized stage, about 21% regional,
about 52% distant (metastatic), and the rest unstaged/unknown. The CDC similarly notes that nearly half of lung cancers
are diagnosed at a distant stage in recent years.

When more people are diagnosed earlier and survive longer, prevalence rises. That’s one reason prevalence is a useful
“how are we doing?” metric: it reflects not just risk, but also progress in treatment and detection.

Who gets lung cancer? Age, sex, race/ethnicity, and geography

Age

Lung cancer is strongly age-related. Most people diagnosed are 65 or older, and the average age at diagnosis is around 70.
That doesn’t mean younger people are immuneit means lung cancer often reflects exposures and risk accumulated over time.

Sex

Annual estimates show lung cancer remains common in both men and women. In the 2025 ACS projections,
women slightly outnumber men in new casesan important reminder that lung cancer is not a “men only” disease.

Race/ethnicity and disparities

Lung cancer is more common in men than women overall, and rates can differ across racial and ethnic groups.
SEER notes higher burden in certain populations (for example, non-Hispanic Black men), and the American Lung Association highlights
persistent gaps in early diagnosis and access to surgery and treatment for people of color.

Where you live

Lung cancer outcomes vary by statepartly due to smoking patterns, workplace exposures, radon prevalence, access to screening,
and the “can you get an appointment without sacrificing three workdays?” reality of healthcare access.

Screening is a clear example: the American Lung Association reports that only 18.2% of eligible people were screened in 2022,
with wide variation by state (Rhode Island reported around 31.0% screened, while Wyoming was around 9.7%).

Risk factors in numbers: smoking, radon, and invisible villains

Smoking

Smoking remains the dominant risk factor. The American Cancer Society estimates that around 80% of lung cancer deaths are due to smoking,
and other tobacco smoke exposures contribute as well. The good news (yes, we’re allowed to have good news) is that quitting helps at any age,
and population-level declines in smoking are a major driver of improved mortality trends.

Radon

Radon is the health risk nobody can smell, see, or argue with on social mediabecause it’s a radioactive gas.
It’s considered the second leading cause of lung cancer, and U.S. estimates attribute more than 21,000 lung cancer deaths per year to radon.
The U.S. EPA emphasizes radon as a leading cause of lung cancer among people who don’t smoke, and both EPA and CDC stress home testing and mitigation.

Other exposures

Secondhand smoke, asbestos and other workplace exposures, and air pollution can also raise risk.
The exact contribution varies by individual and environment, but the public-health takeaway is consistent:
lung cancer risk isn’t only about cigarettesit’s also about the air and settings people live and work in.

Screening: the “we have a tool, but people aren’t using it” problem

Who should get screened?

The U.S. Preventive Services Task Force recommends annual low-dose CT (LDCT) screening for adults ages 50 to 80
who have at least a 20 pack-year smoking history and currently smoke or quit within the past 15 years.
Screening should stop once someone has not smoked for 15 years or develops a health problem that substantially limits life expectancy
or willingness/ability to have curative lung surgery.

How many eligible people actually get screened?

Not nearly enough. The American Lung Association reports about 18.2% of eligible people were screened in 2022.
Separate ACS reporting using national survey data found about 18.7% of screening-eligible individuals reported being up to date.

In plain terms: roughly 4 out of 5 eligible people are missing a screening that can help catch lung cancer earlier.
Barriers include awareness, access, fear of results, time off work, transportation, and inconsistent referral patterns.
“The scan takes minutes” doesn’t help if getting to the scan takes a day.

What these statistics mean for real-life decisions

Statistics can’t tell you what’s going to happen to any one personbut they can shape smart choices:

• If you’re screening-eligible, ask about LDCT. Early-stage detection is strongly linked to better outcomes.
• If you own or rent a home, consider radon testing. It’s one of the few lung cancer risk factors you can measure and reduce
  without needing a medical appointment.
• If you smoke, quitting mattersnow. The risk doesn’t vanish overnight, but it drops over time, and it also improves overall health.
• If you don’t smoke, don’t ignore symptoms. Lung cancer can occur in people who never smoked; timely evaluation matters.

Frequently asked questions about lung cancer prevalence and stats

Is lung cancer still the leading cause of cancer death in the U.S.?

Yes. Multiple federal and major cancer-organization summaries note lung cancer causes more deaths than any other cancer type in the U.S.,
even though it is not always the most commonly diagnosed.

Why can prevalence increase even if fewer people are diagnosed?

Because prevalence depends on both new cases and survival. If treatments improve and people live longer,
the number of people living with the disease can rise even as incidence trends downward.

Do never-smokers get lung cancer?

Yes. Smoking is the biggest driver, but it’s not the only one. Advocacy organizations and public health agencies highlight radon, secondhand smoke,
workplace exposures, and air pollution as contributors, and they emphasize that “anyone with lungs can get lung cancer.”

Real-life experiences behind the numbers (about )

Statistics can sound cold until you remember what they’re made of: actual people, actual households, and actual “how are we going to handle this?”
conversations at kitchen tables. Here are a few common experiences that show up again and again behind the prevalence and survival charts.

1) The “I feel fine” screening surprise. A lot of people who qualify for screening don’t have symptoms.
That’s the pointand also why it’s hard to motivate. One typical story looks like this: a 62-year-old former smoker goes in for an annual
low-dose CT because a primary care clinician finally brings it up (or a spouse becomes the household’s unofficial project manager).
A small spot shows up, and suddenly the conversation shifts from “I’m healthy” to “I’m localized, and that’s a good thing.”
The scans can be anxiety-provoking, but for those diagnosed early, the path often includes surgery or targeted radiation and a real shot
at long-term survival. People don’t love the waitingbut they love the second chance.

2) The never-smoker diagnosis whiplash. For people who never smoked, a lung cancer diagnosis can feel like being handed a bill
for a vacation you didn’t take. These patients often talk about the confusion: “How is this possible?”
That’s where risk factors like radon and environmental exposures enter the chat (uninvited, as usual).
Many describe a frustrating loop before diagnosistreating a cough as allergies, then reflux, then “maybe it’s just a lingering thing.”
When the diagnosis finally lands, it can come with an extra layer of emotional work: correcting assumptions, educating friends, and navigating
the stigma that still clings to lung cancer.

3) The caregiver timeline nobody schedules for. Prevalence means a lot of people are living with lung cancer and its aftermath.
Caregivers often describe life becoming a calendar full of scans, lab work, infusion visits, medication refills, insurance calls, and the occasional
“why is the parking garage always under construction?” moment. Even in the best-case scenario, it’s a marathon of logistics.
When treatment is long-term, families build routines around side effects and energy levelslearning what “good day” and “bad day” really mean.

4) The “numbers become personal” turning point. Many survivors and families say the same thing: at first, they looked up survival rates
like it was the weather forecasthoping the odds would change if they refreshed the page enough times.
Over time, the healthier mindset becomes: use statistics for context, not as a sentence.
People focus on controllables: showing up for appointments, asking about biomarker testing when appropriate, managing symptoms early,
leaning on support groups, and making home changes (like radon mitigation) that feel empowering in a situation that can feel anything but.

The bottom line is that the stats are real, and so is the progress. Prevalence reflects both the burden and the growing community of people
living longerpeople who deserve early detection, modern treatment, and a healthcare system that doesn’t make “getting care” the hardest part.

Conclusion

Lung cancer remains a major public health challenge in the United States, with hundreds of thousands of new cases and more deaths than any other cancer.
But the statistics also show momentum: survival is improving, and prevention and early detection tools exist. Understanding prevalence helps you see the
full picturehow many people are living with lung cancer, how long they’re living, and what factors (like stage at diagnosis and screening rates) can move
outcomes in the right direction. The goal isn’t to memorize numbers; it’s to use them to make better decisions, ask better questions, and push for better access.